Based on our NPV based valuation, we believe that Addex remains substantially undervalued at the current share price of CHF 1.40. We believe the share price decrease of the last few months is unjustified and provides a substantial buying opportunity as we expect significant news flow in the coming months as the COVID-19 pandemic diminishes. The announcement of Janssen’s decision to advance ADX71149 into a Phase IIa study has a positive effect on the valuation, and we expect the start of both dipraglurant Phase IIb/III pivotal study and ADX71149 Phase IIa Epilepsy study to have a positive impact on the Addex share price. Using our valuation model and taking into account the future revenues from its late-stage clinical pipeline and its current partnerships with Indivior and Janssen, we have increased our valuation to CHF 425-460 million, or CHF 13.00-14.00 per share.
G
This stock should trade min. X10 the actual price! Short covering should start soon. ADXN is really shorted with a low float!
D
Go Guys... One of the most shorted stock with low Float!
M
Addex ADX71149 Receives IND Approval to Start a Phase 2a Clinical Study in Epilepsy Thu Jan 21 07:02:03 2021 EDT First patient treated with ADX71149 (JNJ-40411813) scheduled for Q2 2021 Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today announced that its partner Janssen Pharmaceuticals, Inc. , part of the Janssen Pharmaceutical Companies of Johnson & Johnson , has received FDA’s Investigational New Drug (IND) approval to begin a Phase 2a proof of concept study with the selective metabotropic glutamate type 2 (mGlu2) receptor positive allosteric modulator (PAM), JNJ-40411813 (ADX71149), in patients with epilepsy. The first patient is expected to be treated during Q2 2021.
Pre Market Resistance at 18.20 - then there is little resistance upwards.
S
$ADXN ADXN.S.W TICKER CHF SWISS THIS IS THERE PHARMACEUTICAL STOCK ITS ROCKETING TODAY thats the ticker its there pharmaceutical side look at it already jumped 20%
P
Nobody seems to care about this company. Under the radar is an understatement. I am accumulating. Join me for some fun. We can go to Switzerland for the next annual meeting. Beautiful place, I've been there. I see this as a takeover candidate because of their deep pipeline. If there are people that disagree, please post yoir opinion. I am always looking to reevaluate based on new info.
l
This is my first operation in ADXN and I won... Now seem I have to pay taxes to take out the money. Can someone explain me if this is true?
P
There are a whole lot of ADXN "catalysts" (I hate that word) either imminent or scheduled for Q2. Epilepsy, Parkinson's, twitchy eyelids (don't laugh, that can be a big problem). I think now is a good price and time to accumulate. This Swiss company is flying under the radar but not for much longer I believe.
H
This company partnered years back with J and J and actually have very different pipeline. Suppose to be a read out soon.
T
What part of the game is this? Got in at $15.50 and thought I was doing something. Feels like it’s being held down. Might have to wait for AH
K
3 o’clock sour hour. Can it fill the gap?
J
why no one buys this
H
What moving this today? Was going to add to this but had it for the last few years in foreign shares.
R
absolutely undervalued because of the current situation in the market.
B
Check out this youtube video that explains trading biotech stocks with decent strategies and explanations.
I wish I watched this years ago, it would have save me a lot of time.
Pipeline
https://www.addextherapeutics.com/files/cache/5c7f9ce6567681d6991b811d7544272b_f342.png
Analyst report
https://www.addextherapeutics.com/files/8415/9522/1747/20200720_update_report_Addex_FINAL.pdf
Based on our NPV based valuation, we believe that Addex remains substantially undervalued at
the current share price of CHF 1.40. We believe the share price decrease of the last few months is
unjustified and provides a substantial buying opportunity as we expect significant news flow in the
coming months as the COVID-19 pandemic diminishes. The announcement of Janssen’s decision
to advance ADX71149 into a Phase IIa study has a positive effect on the valuation, and we expect
the start of both dipraglurant Phase IIb/III pivotal study and ADX71149 Phase IIa Epilepsy study to
have a positive impact on the Addex share price. Using our valuation model and taking into
account the future revenues from its late-stage clinical pipeline and its current partnerships with
Indivior and Janssen, we have increased our valuation to CHF 425-460 million, or CHF 13.00-14.00
per share.
Thu Jan 21 07:02:03 2021 EDT
First patient treated with ADX71149 (JNJ-40411813) scheduled for Q2 2021
Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today announced that its partner Janssen Pharmaceuticals, Inc. , part of the Janssen Pharmaceutical Companies of Johnson & Johnson , has received FDA’s Investigational New Drug (IND) approval to begin a Phase 2a proof of concept study with the selective metabotropic glutamate type 2 (mGlu2) receptor positive allosteric modulator (PAM), JNJ-40411813 (ADX71149), in patients with epilepsy. The first patient is expected to be treated during Q2 2021.
Pre Market Resistance at 18.20 - then there is little resistance upwards.
I wish I watched this years ago, it would have save me a lot of time.
Enjoy
https://youtu.be/NPnKFYrib5Q